Does CARFILZOMIB Cause Malignant neoplasm progression? 109 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 109 reports of Malignant neoplasm progression have been filed in association with CARFILZOMIB (KYPROLIS). This represents 0.5% of all adverse event reports for CARFILZOMIB.
109
Reports of Malignant neoplasm progression with CARFILZOMIB
0.5%
of all CARFILZOMIB reports
39
Deaths
19
Hospitalizations
How Dangerous Is Malignant neoplasm progression From CARFILZOMIB?
Of the 109 reports, 39 (35.8%) resulted in death, 19 (17.4%) required hospitalization, and 9 (8.3%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for CARFILZOMIB. However, 109 reports have been filed with the FAERS database.
What Other Side Effects Does CARFILZOMIB Cause?
Plasma cell myeloma (2,238)
Off label use (2,120)
Death (1,442)
Thrombocytopenia (1,265)
Fatigue (1,048)
Pneumonia (1,016)
Pyrexia (969)
Anaemia (910)
Dyspnoea (881)
Neutropenia (874)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which CARFILZOMIB Alternatives Have Lower Malignant neoplasm progression Risk?
CARFILZOMIB vs CARGLUMIC ACID
CARFILZOMIB vs CARIPRAZINE
CARFILZOMIB vs CARISOPRODOL
CARFILZOMIB vs CARMUSTINE
CARFILZOMIB vs CARTEOLOL